F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy. Source: Read the original article on www.nytimes.com